Intellia Therapeutics Inc

NTLA: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
XLPLOCK|bDnLOCK|%z#G>d

Intellia Earnings: Patient Screening May Mitigate Nex-Z Liver Risk; Regulatory Progress for Lonvo-Z

Intellia reported $7.7 million in second-quarter collaboration revenue and submitted its US filing for lonvo-z in hereditary angioedema. Intellia ended the quarter with a net loss of $106 million and $628 million in cash and cash equivalents.

Sponsor Center